open access

Ahead of print
Research paper (original)
Published online: 2021-09-03
Get Citation

Serum ROBO4 and CLEC14A: preliminary evaluation as diagnostic and progression biomarkers in colorectal cancer patients

Łukasz Pietrzyk12, Kamil Torres1
DOI: 10.5603/NJO.a2021.0052
Affiliations
  1. Chair and Department of Didactics and Medical Simulation, Medical University of Lublin, Poland, Chodźki 4, 20-093 Lublin, Poland
  2. Department of General, Oncological, and Minimally Invasive Surgery, 1st Military Clinical Hospital with the Outpatient Clinic, Lublin, Poland

open access

Ahead of print
Original article
Published online: 2021-09-03

Abstract

Introduction. Colorectal cancer (CRC) is an important global burden, and the discovery of biomarkers for screening and monitoring is a current challenge. The present study aimed to determine the serum concentration of ROBO4 and CLEC14A in CRC patients and assess the diagnostic and progression value of these biomarkers in CRC.

Material and methods. Serum samples were collected from 32 patients with CRC and from 16 healthy individuals. Blood serum of CRC patients were tested before and after surgery. Serum concentration of ROBO4 and CLEC14A were measured using ELISA tests.

Results. The serum concentrations of ROBO4 and CLEC14A were significantly higher in CRC patients than non-cancer controls. The sensitivitiy and specificity of ROBO4 and CLEC14A in distiguishing cancer patients from controls ranged from 71.9% to 100% and from 84.5% to 100%, respectively. The serum ROBO4 concentration was associated with the TNM stage, depth of invasion, and lymph node and distant metastases. The level of ROBO4 was statistically lower 3 months after the surgery, compared to the level noted prior to the operation.

Conclusions. Our preliminary study has provided evidence that ROOB4 and CLEC14A seem to be suitable biomarkers for clinical diagnostic purposes in colorectal cancer.

Abstract

Introduction. Colorectal cancer (CRC) is an important global burden, and the discovery of biomarkers for screening and monitoring is a current challenge. The present study aimed to determine the serum concentration of ROBO4 and CLEC14A in CRC patients and assess the diagnostic and progression value of these biomarkers in CRC.

Material and methods. Serum samples were collected from 32 patients with CRC and from 16 healthy individuals. Blood serum of CRC patients were tested before and after surgery. Serum concentration of ROBO4 and CLEC14A were measured using ELISA tests.

Results. The serum concentrations of ROBO4 and CLEC14A were significantly higher in CRC patients than non-cancer controls. The sensitivitiy and specificity of ROBO4 and CLEC14A in distiguishing cancer patients from controls ranged from 71.9% to 100% and from 84.5% to 100%, respectively. The serum ROBO4 concentration was associated with the TNM stage, depth of invasion, and lymph node and distant metastases. The level of ROBO4 was statistically lower 3 months after the surgery, compared to the level noted prior to the operation.

Conclusions. Our preliminary study has provided evidence that ROOB4 and CLEC14A seem to be suitable biomarkers for clinical diagnostic purposes in colorectal cancer.

Get Citation

Keywords

ROBO4; CLEC14A; biomarker; colorectal cancer; angiogenesis

About this article
Title

Serum ROBO4 and CLEC14A: preliminary evaluation as diagnostic and progression biomarkers in colorectal cancer patients

Journal

Nowotwory. Journal of Oncology

Issue

Ahead of print

Article type

Research paper (original)

Published online

2021-09-03

DOI

10.5603/NJO.a2021.0052

Keywords

ROBO4
CLEC14A
biomarker
colorectal cancer
angiogenesis

Authors

Łukasz Pietrzyk
Kamil Torres

References (38)
  1. Brenner H, Chen C. The colorectal cancer epidemic: challenges and opportunities for primary, secondary and tertiary prevention. Br J Cancer. 2018; 119(7): 785–792.
  2. Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017; 67(3): 177–193.
  3. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6): 394–424.
  4. Araghi M, Arnold M, Rutherford MJ, et al. Colon and rectal cancer survival in seven high-income countries 2010-2014: variation by age and stage at diagnosis (the ICBP SURVMARK-2 project). Gut. 2021; 70(1): 114–126.
  5. Maida M, Macaluso FS, Ianiro G, et al. Screening of colorectal cancer: present and future. Expert Rev Anticancer Ther. 2017; 17(12): 1131–1146.
  6. Ogunwobi OO, Mahmood F, Akingboye A. Biomarkers in Colorectal Cancer: Current Research and Future Prospects. Int J Mol Sci. 2020; 21(15).
  7. Scheer A, Auer RA. Surveillance after curative resection of colorectal cancer. Clin Colon Rectal Surg. 2009; 22(4): 242–250.
  8. Patel JN, Fong MKa, Jagosky M. Colorectal Cancer Biomarkers in the Era of Personalized Medicine. J Pers Med. 2019; 9(1).
  9. Yiu AJ, Yiu CY. Biomarkers in Colorectal Cancer. Anticancer Res. 2016; 36(3): 1093–1102.
  10. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2002; 29(6 Suppl 16): 15–18.
  11. Naumov GN, Akslen LA, Folkman J. Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle. 2006; 5(16): 1779–1787.
  12. Pietrzyk Ł. Biomarkers Discovery for Colorectal Cancer: A Review on Tumor Endothelial Markers as Perspective Candidates. Dis Markers. 2016; 2016: 4912405.
  13. Pietrzyk Ł, Wdowiak P. Endosialin (TEM1) as a Diagnostic, Progression, and Prognostic Serum Marker for Patients With Colorectal Cancer-A Preliminary Study. Cancer Control. 2020; 27(1): 1073274820903351.
  14. Pietrzyk Ł, Wdowiak P. Serum TEM5 and TEM7 concentrations correlate with clinicopathologic features and poor prognosis of colorectal cancer patients. Adv Med Sci. 2019; 64(2): 402–408.
  15. Mura M, Swain RK, Zhuang X, et al. Identification and angiogenic role of the novel tumor endothelial marker CLEC14A. Oncogene. 2012; 31(3): 293–305.
  16. Pircher A, Fiegl M, Untergasser G, et al. Favorable prognosis of operable non-small cell lung cancer (NSCLC) patients harboring an increased expression of tumor endothelial markers (TEMs). Lung Cancer. 2013; 81(2): 252–258.
  17. Seth P, Lin Y, Hanai Ji, et al. Magic roundabout, a tumor endothelial marker: expression and signaling. Biochem Biophys Res Commun. 2005; 332(2): 533–541.
  18. Pircher A, Schäfer G, Eigentler A, et al. Robo 4 - the double-edged sword in prostate cancer: impact on cancer cell aggressiveness and tumor vasculature. Int J Med Sci. 2019; 16(1): 115–124.
  19. Huminiecki L, Gorn M, Suchting S, et al. Magic roundabout is a new member of the roundabout receptor family that is endothelial specific and expressed at sites of active angiogenesis. Genomics. 2002; 79(4): 547–552.
  20. Park KW, Morrison CM, Sorensen LK, et al. Robo4 is a vascular-specific receptor that inhibits endothelial migration. Dev Biol. 2003; 261(1): 251–267.
  21. Huminiecki L. Magic roundabout is an endothelial-specific ohnolog of ROBO1 which neo-functionalized to an essential new role in angiogenesis. PLOS ONE. 2019; 14(2): e0208952.
  22. Wang B, Xiao Y, Ding BB, et al. Induction of tumor angiogenesis by Slit-Robo signaling and inhibition of cancer growth by blocking Robo activity. Cancer Cell. 2003; 4(1): 19–29.
  23. Masiero M, Simões FC, Han HD, et al. A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis. Cancer Cell. 2013; 24(2): 229–241.
  24. Borah S, Vasudevan D, Swain RK. C-type lectin family XIV members and angiogenesis. Oncol Lett. 2019; 18(4): 3954–3962.
  25. Noy PJ, Lodhia P, Khan K, et al. Blocking CLEC14A-MMRN2 binding inhibits sprouting angiogenesis and tumour growth. Oncogene. 2015; 34(47): 5821–5831.
  26. Winslow S, Lindquist KE, Edsjö A, et al. The expression pattern of matrix-producing tumor stroma is of prognostic importance in breast cancer. BMC Cancer. 2016; 16(1): 841.
  27. Jiang Z, Liang G, Xiao Y, et al. Targeting the SLIT/ROBO pathway in tumor progression: molecular mechanisms and therapeutic perspectives. Ther Adv Med Oncol. 2019; 11: 1758835919855238.
  28. Lee S, Rho SS, Park H, et al. Carbohydrate-binding protein CLEC14A regulates VEGFR-2- and VEGFR-3-dependent signals during angiogenesis and lymphangiogenesis. J Clin Invest. 2017; 127(2): 457–471.
  29. Gröne J, Doebler O, Loddenkemper C, et al. Robo1/Robo4: differential expression of angiogenic markers in colorectal cancer. Oncol Rep. 2006; 15(6): 1437–1443.
  30. Robinson J, Whitworth K, Jinks E, et al. An evaluation of the tumour endothelial marker CLEC14A as a therapeutic target in solid tumours. J Pathol Clin Res. 2020; 6(4): 308–319.
  31. Dai C, Gong Q, Cheng Y, et al. Regulatory mechanisms of Robo4 and their effects on angiogenesis. Biosci Rep. 2019; 39(7).
  32. Pircher A, Schäfer G, Eigentler A, et al. Robo 4 - the double-edged sword in prostate cancer: impact on cancer cell aggressiveness and tumor vasculature. Int J Med Sci. 2019; 16(1): 115–124.
  33. Chen YK, Hou HA, Tang JL, et al. Clinical and prognostic implications of Roundabout 4 (robo4) in adult patients with acute myeloid leukemia. PLoS One. 2015; 10(3): e0119831.
  34. Zhao H, Ahirwar DK, Oghumu S, et al. Endothelial Robo4 suppresses breast cancer growth and metastasis through regulation of tumor angiogenesis. Mol Oncol. 2016; 10(2): 272–281.
  35. Su C, Shi K, Cheng Xu, et al. Methylation of CLEC14A is associated with its expression and lung adenocarcinoma progression. J Cell Physiol. 2019; 234(3): 2954–2962.
  36. Krishna Priya S, Kumar K, Hiran KR, et al. Expression of a novel endothelial marker, C-type lectin 14A, in epithelial ovarian cancer and its prognostic significance. Int J Clin Oncol. 2017; 22(1): 107–117.
  37. Lone GN, Sheikh AA, Sheikh ZA, et al. Role of preoperative chemotherapy in squamous cell carcinoma of esophagus in kashmir, a cancer belt - a pilot study. Asian Pac J Cancer Prev. 2011; 12(2): 465–470.
  38. Ichikawa N, Kamiyama T, Yokoo H, et al. Preoperative chemotherapy in colorectal cancer patients with synchronous liver metastasis. Mol Clin Oncol. 2020; 12(4): 374–383.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media sp. z o.o. VM Group sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl